Table 2.
Univariate analysis for association of baseline ocular and fundus characteristics with visual outcomes at 1 year
| # of Subjects at 1 year (N=1105) | VA score at 1 year | Change in VA score at 1 year | ≥3-lines gain frombaseline at 1 year | ||||
|---|---|---|---|---|---|---|---|
| Baseline Ocular Characteristics | n (%) | Mean (SE) | P-value* | Mean (SE) | P-value* | n (%) | P-Value† |
| Baseline VA in study eye | <0.001 | <0.001 | <0.001 | ||||
| 68–82 letters, 20/25 - 20/40 | 397 (35.9%) | 77.7 (0.7) | 3.7 (0.7) | 28 (7.1%) | |||
| 53–67 letters, 20/50 - 20/80 | 414 (37.5%) | 69.2 (0.7) | 8.5 (0.7) | 150 (36.2%) | |||
| 38–52 letters, 20/100-20/160 | 223 (20.2%) | 57.8 (1.0) | 11.4 (1.0) | 119 (53.4%) | |||
| 23–37 letters, 20/200-20/320 | 71 (6.4%) | 39.3 (1.7) | 7.8 (1.7) | 30 (42.3%) | |||
| As continuous (1 letter increase) | 0.79 (0.03) | <0.001 | −0.22 (0.03) | <0.001 | <0.001 | ||
| Baseline VA in fellow eye | 0.003 | 0.03 | 0.02 | ||||
| 83–100 letters, 20/20 or better | 331 (30.0%) | 70.7 (1.0) | 8.9 (0.8) | 110 (33.2%) | |||
| 68–82 letters, 20/25-20/40 | 433 (39.2%) | 67.5 (0.9) | 7.2 (0.7) | 135 (31.2%) | |||
| 0–67 letters, 20/50 or worse | 341 (30.9%) | 66.1 (1.0) | 5.9 (0.8) | 82 (24.0%) | |||
| As continuous (1 letter increase) | 0.04 (0.02) | 0.051 | 0.04 (0.02) | 0.04 | 0.005 | ||
| Baseline CNV area (mm2) | <0.001 | 0.007 | 0.27 | ||||
| ≤2.54 | 443 (40.1%) | 70.9(0.8) | (<0.001) | 8.8 (0.7) | (0.007) | 145 (32.7%) | (0.11) |
| >2.54 to ≤5.08 | 219 (19.8%) | 68.4(1.2) | 7.7 (1.0) | 63 (28.8%) | |||
| >5.08 to ≤10.2 | 207 (18.7%) | 66.9(1.2) | 6.6 (1.0) | 65 (31.4%) | |||
| >10.2 | 103 (9.3%) | 63.4(1.8) | 3.4 (1.4) | 24 (23.3%) | |||
| Unknown | 133 (12.0%) | 63.2(1.5) | 5.8 (1.3) | 30 (22.6%) | |||
| As continuous (every 2.54 mm2 increase) | −1.25 (0.33) | <0.001 | −0.60 (0.24) | 0.01 | 0.02 | ||
| Baseline total area of CNV lesion (mm2) | <0.001 | 0.04 | 0.13 | ||||
| ≤2.54 | 355 (32.1%) | 71.3 (0.9) | (<0.001) | 8.1(0.8) | (0.04) | 107(30.1%) | (0.045) |
| >2.54 to ≤5.08 | 240 (21.7%) | 69.6 (1.2) | 8.7(1.0) | 76(31.7%) | |||
| >5.08 to ≤10.2 | 265 (24.0%) | 66.3 (1.1) | 7.3(0.9) | 89(33.6%) | |||
| >10.2 | 202 (18.3%) | 62.7 (1.3) | 5.0(1.0) | 48(23.8%) | |||
| Unknown | 43 (3.9%) | 68.0 (2.7) | 4.3(2.2) | 7 (16.3%) | |||
| As continuous (every 2.54 mm2 increase) | −1.39 (0.21) | <0.001 | −0.58 (0.18) | 0.001 | 0.02 | ||
| Location of lesion | <0.001 | 0.90 | 0.08 | ||||
| Not Subfoveal | 299 (27.1%) | 71.7 (1.0) | (<0.001) | 7.3(0.9) | (0.48) | 77(25.8%) | (0.04) |
| Subfoveal | 788 (71.3%) | 66.5 (0.6) | 7.4(0.5) | 248(31.5%) | |||
| Unknown | 18 (1.6%) | 72.1 (4.2) | 3.2(3.5) | 2 (11.1%) | |||
| Lesion type | <0.001 | 0.94 | <0.001 | ||||
| Predominantly or Minimally classic | 431 (39.0%) | 64.2 (0.9) | (<0.001) | 7.4(0.7) | (0.83) | 156(36.2%) | (<0.001) |
| Occult only | 650 (58.8%) | 70.4 (0.7) | 7.3(0.6) | 167(25.7%) | |||
| Unknown | 24 (2.2%) | 71.6 (3.6) | 5.5(3.0) | 4(16.7%) | |||
| Lesion Composition | 0.19 | 0.09 | 0.003 | ||||
| CNV only | 560 (50.7%) | 69.0 (0.8) | (0.25) | 6.9(0.6) | (0.08) | 152(27.1%) | (0.001) |
| CNV and hemorrhage | 286 (25.9%) | 66.9 (1.1) | 7.4(0.9) | 92(32.2%) | |||
| CNV and blocked fluorescence | 76 (6.9%) | 67.1 (2.1) | 6.5(1.7) | 22(28.9%) | |||
| CNV and SPED | 47 (4.3%) | 70.2 (2.6) | 5.9(2.2) | 8(17.0%) | |||
| CNV and others | 121 (11.0%) | 65.4 (1.6) | 10.8(1.3) | 52(43.0%) | |||
| Unknown | 15 (1.4%) | 71.2 (4.6) | 2.4(3.8) | 1(6.7%) | |||
| RAP lesion | 0.13 | 0.02 | 0.008 | ||||
| No | 966 (87.4%) | 67.6 (0.6) | (0.15) | 7.0(0.5) | (0.06) | 276(28.6%) | (0.009) |
| Yes | 118 (10.7%) | 70.3 (1.7) | 10.3(1.4) | 48(40.7%) | |||
| Unknown | 21 (1.9%) | 72.7 (3.9) | 5.7(3.2) | 3(14.3%) | |||
| Hemorrhage contiguous with lesion | 0.07 | 0.11 | 0.007 | ||||
| No | 699 (63.3%) | 68.7 (0.7) | (0.18) | 6.9(0.6) | (0.09) | 190(27.2%) | (0.002) |
| Yes | 388 (35.1%) | 66.7 (0.9) | 8.4(0.8) | 136(35.1%) | |||
| Unknown | 18 (1.6%) | 70.1 (4.2) | 2.3(3.5) | 1 (5.6%) | |||
| Blocked fluorescence lesion | 0.38 | 0.08 | 0.003 | ||||
| No | 935 (84.6%) | 68.2 (0.6) | (0.47) | 7.1(0.5) | (0.13) | 263 (28.1%) | (0.002) |
| Yes | 157 (14.2%) | 66.8 (1.4) | 9.2(1.2) | 63 (40.1%) | |||
| Unknown | 13 (1.2%) | 72.2 (4.9) | 3.1(4.1) | 1 (7.7%) | |||
| SPED (proportion of total lesion) | 0.81 | 0.77 | 0.33 | ||||
| None | 1027 (92.9%) | 67.9 (0.6) | (0.84) | 7.5 (0.5) | (0.47) | 313 (30.5%) | (0.07) |
| <50% | 21 (1.9%) | 68.2 (3.9) | 7.2 (3.2) | 5 (23.8%) | |||
| >=50% | 40 (3.6%) | 69.8 (2.8) | 5.8 (2.3) | 8 (20.0%) | |||
| Unknown | 17 (1.5%) | 70.7 (4.3) | 2.3 (3.6) | 1 (5.9%) | |||
| Fibrotic or atrophic scar | <0.001 | 0.29 | 0.17 | ||||
| No | 1049 (94.9%) | 68.4 (0.6) | (0.001) | 7.3 (0.5) | (0.33) | 309 (29.5%) | (0.08) |
| Yes | 43 (3.9%) | 58.6 (2.7) | 9.7 (2.3) | 17 (39.5%) | |||
| Unknown | 13 (1.2%) | 72.2 (4.9) | 3.1 (4.1) | 1 (7.7%) | |||
| Hemorrhage (associated with the lesion) | 0.001 | 0.009 | 0.001 | ||||
| None | 420 (38.0%) | 69.3 (0.9) | (0.002) | 5.7 (0.7) | (0.01) | 99 (23.6%) | (<0.001) |
| ≤1 DA | 561 (50.8%) | 68.1 (0.8) | 8.8 (0.6) | 198 (35.3%) | |||
| >1 to ≤2 DA | 55 (5.0%) | 64.1 (2.4) | 7.9 (2.0) | 17 (30.9%) | |||
| >2 DA | 50 (4.5%) | 59.4 (2.5) | 4.9 (2.1) | 11 (22.0%) | |||
| Unknown | 19 (1.7%) | 70.4 (4.1) | 3.8 (3.4) | 2 (10.5%) | |||
| Geographic atrophy | 0.008 | 0.049 | 0.44 | ||||
| None/questionable | 1027 (92.9%) | 68.4 (0.6) | (0.02) | 7.6 (0.5) | (0.14) | 308 (30.0%) | |
| Present | 76 (6.9%) | 62.8 (2.0) | 4.1 (1.7) | 19 (25.0%) | |||
| Unknown | 2 (0.2%) | 53.0 (13) | 6.0 (10) | 0 (0%) | |||
| Glaucoma | 0.15 | 0.97 | 0.53 | ||||
| No | 981 (88.8%) | 68.3 (0.6) | 7.3 (0.5) | 287 (29.3%) | |||
| Yes | 124 (11.2%) | 65.8 (1.6) | 7.3 (1.3) | 40 (32.3%) | |||
| Unknown | 19 (1.7%) | 70.4 (4.1) | 3.8 (3.4) | 2 (10.5%) | |||
| CNV in fellow eye | 0.30 | 0.67 | 0.04 | ||||
| None/questionable | 746 (67.5%) | 67.7(0.7) | (0.56) | 7.4 (0.5) | (0.50) | 235 (31.5%) | (0.09) |
| Present | 334 (30.2%) | 68.9(1.0) | 7.0 (0.8) | 84 (25.1%) | |||
| Unknown | 25 (2.3%) | 67.0 (3.6) | 10.5 (2.9) | 8 (32.0%) | |||
VA = Visual Acuity; SE = Standard Error; VA= Visual Acuity; CNV= choroidal neovascularization; DA= Disc Area; SPED= serous retinal pigment epithelial detachment; RAP=Retinal Angiomatous Proliferans; RPE=Retinal Pigment Epithelium.
*
P-value was from one-way analysis of variance (ANOVA).
†
P value was from Monte-Carlo fisher exact test.
P-value in the parenthesis was calculated including the unknown category, while P-value not in parenthesis was calculated excluding the unknown category.